Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

982 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.
Wada M, Yamamoto M, Ryuge S, Nagashima Y, Hayashi N, Maki S, Otani S, Katono K, Takakura A, Yanaihara T, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Masuda N. Wada M, et al. Among authors: otani s. Cancer Chemother Pharmacol. 2012 Apr;69(4):1005-11. doi: 10.1007/s00280-011-1795-5. Epub 2011 Dec 8. Cancer Chemother Pharmacol. 2012. PMID: 22160350 Clinical Trial.
Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
Asakuma M, Yamamoto M, Wada M, Ryuge S, Katono K, Yokoba M, Fukui T, Takakura A, Otani S, Maki S, Igawa S, Yanaihara T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Masuda N. Asakuma M, et al. Among authors: otani s. Cancer Chemother Pharmacol. 2012 Jun;69(6):1529-36. doi: 10.1007/s00280-012-1858-2. Epub 2012 Mar 14. Cancer Chemother Pharmacol. 2012. PMID: 22415148 Clinical Trial.
Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation.
Igawa S, Kasajima M, Ishihara M, Kimura M, Hiyoshi Y, Niwa H, Kusuhara S, Harada S, Asakuma M, Otani S, Katono K, Sasaki J, Masuda N. Igawa S, et al. Among authors: otani s. Cancer Chemother Pharmacol. 2014 Nov;74(5):939-46. doi: 10.1007/s00280-014-2570-1. Epub 2014 Aug 31. Cancer Chemother Pharmacol. 2014. PMID: 25173459
Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Otani S, Hamada A, Sasaki J, Wada M, Yamamoto M, Ryuge S, Takakura A, Fukui T, Yokoba M, Mitsufuji H, Toyooka I, Maki S, Kimura M, Hayashi N, Ishihara M, Kasajima M, Hiyoshi Y, Katono K, Asakuma M, Igawa S, Kubota M, Katagiri M, Saito H, Masuda N. Otani S, et al. Am J Clin Oncol. 2015 Aug;38(4):405-10. doi: 10.1097/COC.0b013e3182a2d98d. Am J Clin Oncol. 2015. PMID: 26214085 Clinical Trial.
982 results